Skip to content
Company Analysis

Pasithea Therapeutics Corp. KTTA

A comprehensive view of key metrics, scores, and financial health for Pasithea Therapeutics Corp.

Overview of Pasithea Therapeutics Corp.

KTTA NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Pasithea Therapeutics Corp. (KTTA), is a Micro Cap company, in the Biotechnology industry, last closed at $0.39, about 0.0% overvalued vs fair value, -51.7% 1Y return, ranked 398/1145 in sector.
Metrics ROE -58.4%
USD 0.39
-1.01%
(Delayed)
• Vol 90d: 70.3%
52-Week Range
Market Cap
$13.13M
Enterprise Value
$6.07M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Fair
Growth
Good
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Fair
Completeness: 76%
Confidence: 86%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.pasithea.com
HQ Miami Beach, FL
Employees 4
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$55.2M
696.8%%
Total Revenue
$0
Net Income
-$20.4M
-46.9%%
Operating Expense
$20.9M
46.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
43.5 months
Excellent

Strong cash position with 2+ years of runway

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$359.7M
5195.3% of Cash on Hand

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Pasithea Therapeutics Corp.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
38
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.83), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.01), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing KTTA's balance between Growth (45.8%), Profitability (15.5%), and Safety (38.7%). Growth 46% Safety 39% Profitability 15%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

98th percentile vs peers
99
Key Signals
TSR 37.80 98p
Strengths
  • Growth performance in top 20% of peers (percentile: 98)
  • TSR in top 20% of peers (37.80, 98th percentile)
  • Cash to Debt Ratio in top 20% of peers (199.94, 95th percentile)
  • Current Ratio in top 20% of peers (11.35, 86th percentile)
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

83th percentile vs peers
83
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Pasithea Therapeutics Corp..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000